Contact dermatitis induced by glatiramer acetate

2011 ◽  
Vol 17 (11) ◽  
pp. 1390-1392 ◽  
Author(s):  
S Haltmeier ◽  
M Yildiz ◽  
S Müller ◽  
MD Anliker ◽  
L Heinzerling
Keyword(s):  
Contact Dermatitis ◽  
Glatiramer Acetate ◽  
Lymphocyte Transformation ◽  
Lymphocyte Transformation Test ◽  
Topical Steroids ◽  
Scratch Testing ◽  
Subcutaneous Injections ◽  
Relapsing Remitting ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Safe Treatment Option

Glatiramer acetate (Copaxone®) is an immunomodulatory polypeptide used in patients with relapsing–remitting multiple sclerosis. It represents a safe treatment option with mild side effects. In this study, we look at a 39-year-old woman who received glatiramer acetate as subcutaneous injections for two months and developed contact dermatitis. The drug had to be stopped, and treatment with topical prednisone was initiated. Prick/scratch testing was negative but the lymphocyte transformation test was highly positive for glatiramer acetate. This is the first report on contact dermatitis induced by glatiramer acetate injections. The treatment consisted of local topical steroids and cessation of the drug.

scholarly journals Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate, Copaxone®, and TV-5010, Protiramer) in Rats and Monkeys

2011 ◽  
Vol 40 (1) ◽  
pp. 40-54 ◽  
Author(s):  
Yuval Ramot ◽  
Moti Rosenstock ◽  
Ety Klinger ◽  
Dizza Bursztyn ◽  
Abraham Nyska ◽  
...  
Keyword(s):  
Glatiramer Acetate ◽  
Complex Mixture ◽  
Safety Evaluation ◽  
Sprague Dawley ◽  
Subcutaneous Injections ◽  
Toxicity Studies ◽  
Sprague Dawley Rats ◽  
Relapsing Remitting ◽  
Relapsing Remitting Multiple Sclerosis

Glatiramer acetate (GA), the active ingredient in Copaxone®, is a complex mixture of polypeptides used for the treatment of relapsing remitting multiple sclerosis. Glatiramoids are related mixtures that may differ in some characteristics of the prototype molecule. Our aim is to describe the long-term toxicity studies with protiramer (TV-5010), a new glatiramoid, in comparison with similar studies conducted with GA. The toxicity of twice-weekly subcutaneous injections of protiramer to Sprague-Dawley rats (twenty-six weeks) and cynomolgus monkeys (fifty-two weeks) was compared with similar studies done with daily subcutaneous injections of GA. Daily treatment with GA was safe and well tolerated, without systemic effects or death. Protiramer administration was not as well tolerated as GA and led to dose- and time-related mortalities, probably mediated through severe injection-site lesions both in rats and in monkeys. Bridging fibrosis in the liver and severe progressive nephropathy were seen in rats. A dose-related increase in eosinophils was observed in monkeys. The protiramer toxicity studies show that minor variations in the manufacturing of glatiramoids may lead to significant toxic effects. It is therefore essential that the safety of any new glatiramoid be studied in long-term preclinical studies before exposing humans.

scholarly journals When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Mona Alkhawajah ◽  
Joel Oger
Keyword(s):  
Multiple Sclerosis ◽  
Decision Making ◽  
Glatiramer Acetate ◽  
Major Question ◽  
Disease Modifying Drugs ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.

Sign in / Sign up

Export Citation Format

Share Document